Coatue Management Has Cut Stake in Alibaba Group Hldg LTD (BABA) as Market Valuation Rose; As Sangamo Therapeutics (SGMO) Shares Rose, Eam Investors Decreased Position by $754,400

April 17, 2018 - By Dolores Ford

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Logo

Eam Investors Llc decreased its stake in Sangamo Therapeutics Inc. (SGMO) by 22.13% based on its latest 2017Q4 regulatory filing with the SEC. Eam Investors Llc sold 47,150 shares as the company’s stock rose 12.43% while stock markets declined. The institutional investor held 165,877 shares of the health care company at the end of 2017Q4, valued at $2.72 million, down from 213,027 at the end of the previous reported quarter. Eam Investors Llc who had been investing in Sangamo Therapeutics Inc. for a number of months, seems to be less bullish one the $1.55B market cap company. The stock decreased 9.60% or $1.9 during the last trading session, reaching $17.9. About 3.34M shares traded or 45.04% up from the average. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 352.38% since April 17, 2017 and is uptrending. It has outperformed by 340.83% the S&P500.

Philippe Laffont decreased its stake in Alibaba Group Hldg Ltd (BABA) by 21.84% based on its latest 2017Q4 regulatory filing with the SEC. Coatue Management Llc sold 1.27 million shares as the company’s stock rose 3.18% while stock markets declined. The hedge fund run by Philippe Laffont held 4.56 million shares of the business services company at the end of 2017Q4, valued at $785.63M, down from 5.83 million at the end of the previous reported quarter. Coatue Management Llc who had been investing in Alibaba Group Hldg Ltd for a number of months, seems to be less bullish one the $448.89 billion market cap company. The stock increased 1.55% or $2.66 during the last trading session, reaching $174.7. About 9.88 million shares traded. Alibaba Group Holding Limited (NYSE:BABA) has risen 68.29% since April 17, 2017 and is uptrending. It has outperformed by 56.74% the S&P500.

Analysts await Alibaba Group Holding Limited (NYSE:BABA) to report earnings on May, 4 before the open. They expect $0.71 EPS, up 82.05% or $0.32 from last year’s $0.39 per share. BABA’s profit will be $1.82B for 61.51 P/E if the $0.71 EPS becomes a reality. After $1.34 actual EPS reported by Alibaba Group Holding Limited for the previous quarter, Wall Street now forecasts -47.01% negative EPS growth.

Coatue Management Llc, which manages about $14.38 billion and $12.78B US Long portfolio, upped its stake in Snap Inc by 3.79 million shares to 27.39M shares, valued at $400.18M in 2017Q4, according to the filing. It also increased its holding in Broadcom Ltd by 821,739 shares in the quarter, for a total of 3.74 million shares, and has risen its stake in Shopify Inc.

Among 38 analysts covering Alibaba (NYSE:BABA), 36 have Buy rating, 1 Sell and 1 Hold. Therefore 95% are positive. Alibaba had 171 analyst reports since August 12, 2015 according to SRatingsIntel. Deutsche Bank maintained Alibaba Group Holding Limited (NYSE:BABA) on Thursday, September 29 with “Buy” rating. The firm earned “Buy” rating on Monday, January 29 by Morgan Stanley. The company was maintained on Tuesday, August 22 by Oppenheimer. The firm earned “Buy” rating on Monday, February 5 by Bernstein. The company was upgraded on Thursday, January 21 by Standpoint Research. Nomura maintained the shares of BABA in report on Wednesday, August 12 with “Buy” rating. Bank of America maintained Alibaba Group Holding Limited (NYSE:BABA) on Thursday, August 17 with “Buy” rating. Barclays Capital maintained it with “Overweight” rating and $220 target in Tuesday, October 31 report. The rating was downgraded by Standpoint Research on Thursday, April 20 to “Reduce”. As per Tuesday, August 22, the company rating was upgraded by Atlantic Securities.

Analysts await Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report earnings on May, 9. They expect $-0.05 EPS, up 78.26% or $0.18 from last year’s $-0.23 per share. After $-0.15 actual EPS reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -66.67% EPS growth.

Among 10 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 7 have Buy rating, 1 Sell and 2 Hold. Therefore 70% are positive. Sangamo Biosciences had 26 analyst reports since August 8, 2015 according to SRatingsIntel. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) earned “Buy” rating by Jefferies on Thursday, February 22. The company was upgraded on Wednesday, November 15 by PiperJaffray. The stock has “Sell” rating by Zacks on Tuesday, September 8. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has “Buy” rating given on Wednesday, September 2 by Jefferies. The company was reinitiated on Friday, October 23 by Jefferies. As per Wednesday, November 15, the company rating was maintained by Wedbush. Janney Capital downgraded the shares of SGMO in report on Thursday, August 4 to “Neutral” rating. The stock has “Buy” rating by Piper Jaffray on Thursday, February 22. Wells Fargo initiated the shares of SGMO in report on Friday, December 4 with “Outperform” rating. JP Morgan maintained the shares of SGMO in report on Saturday, August 8 with “Overweight” rating.

Investors sentiment decreased to 1.4 in Q4 2017. Its down 0.17, from 1.57 in 2017Q3. It fall, as 16 investors sold SGMO shares while 42 reduced holdings. 35 funds opened positions while 46 raised stakes. 53.22 million shares or 2.49% more from 51.93 million shares in 2017Q3 were reported. Advisory Svcs Ntwk Lc accumulated 4,403 shares. Wells Fargo & Mn holds 0% or 593,562 shares. Vanguard Group holds 4.48M shares. Public Employees Retirement System Of Ohio accumulated 121,388 shares or 0.01% of the stock. Us Bankshares De has 5,000 shares. The Massachusetts-based Rhumbline Advisers has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Renaissance Techs Ltd owns 23,800 shares. Rhenman And Asset Ab owns 0.57% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 255,793 shares. Voloridge Invest Mgmt Ltd Llc invested in 0.07% or 207,433 shares. Moreover, Franklin Street Inc Nc has 0.11% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). 840,104 were reported by Geode Mgmt Ltd. D E Shaw And accumulated 1.36M shares. Fny Managed Accounts Ltd Limited Liability Company owns 203 shares for 0% of their portfolio. State Street Corporation has invested 0.01% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Group One Trading Limited Partnership has invested 0.03% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO).

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: